AU2002301845B2 - Modified release tamsulosin tablets - Google Patents

Modified release tamsulosin tablets Download PDF

Info

Publication number
AU2002301845B2
AU2002301845B2 AU2002301845A AU2002301845A AU2002301845B2 AU 2002301845 B2 AU2002301845 B2 AU 2002301845B2 AU 2002301845 A AU2002301845 A AU 2002301845A AU 2002301845 A AU2002301845 A AU 2002301845A AU 2002301845 B2 AU2002301845 B2 AU 2002301845B2
Authority
AU
Australia
Prior art keywords
tablet
tamsulosin
tablet according
pharmaceutical
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002301845A
Other languages
English (en)
Other versions
AU2002301845A1 (en
Inventor
Juan Cucala Escoi
Jacobus Maria Lemmens
Arturo Siles Ortega
Johannes J. Platteeuw
Frans Van Dalen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23292437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002301845(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon BV filed Critical Synthon BV
Publication of AU2002301845A1 publication Critical patent/AU2002301845A1/en
Application granted granted Critical
Publication of AU2002301845B2 publication Critical patent/AU2002301845B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002301845A 2001-11-07 2002-11-06 Modified release tamsulosin tablets Expired AU2002301845B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33105501P 2001-11-07 2001-11-07
US60/331,055 2001-11-07

Publications (2)

Publication Number Publication Date
AU2002301845A1 AU2002301845A1 (en) 2003-06-12
AU2002301845B2 true AU2002301845B2 (en) 2008-06-05

Family

ID=23292437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002301845A Expired AU2002301845B2 (en) 2001-11-07 2002-11-06 Modified release tamsulosin tablets

Country Status (21)

Country Link
US (2) US20030147955A1 (zh)
EP (3) EP1443917B1 (zh)
JP (3) JP2005512997A (zh)
CN (3) CN1298317C (zh)
AT (3) ATE321544T1 (zh)
AU (1) AU2002301845B2 (zh)
CA (2) CA2465110A1 (zh)
CZ (3) CZ16813U1 (zh)
DE (4) DE60210315T2 (zh)
DK (3) DK1443917T3 (zh)
ES (2) ES2256544T3 (zh)
HU (2) HUP0401978A3 (zh)
IL (4) IL161491A0 (zh)
NL (2) NL1021822C2 (zh)
NO (2) NO20042374L (zh)
NZ (2) NZ532589A (zh)
PT (2) PT1443917E (zh)
RU (2) RU2311903C2 (zh)
SI (2) SI1443917T1 (zh)
WO (2) WO2003039530A1 (zh)
ZA (2) ZA200403281B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532589A (en) * 2001-11-07 2005-02-25 Synthon Bv Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
IN192381B (zh) * 2002-12-20 2004-04-10 Ranbaxy Lab
US20040253309A1 (en) * 2003-01-27 2004-12-16 Yamanouchi Pharmaceutical Co., Ltd. Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof
EA200600066A1 (ru) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
KR100762846B1 (ko) * 2003-09-29 2007-10-04 씨제이 주식회사 서방성 제제
WO2005030179A1 (en) * 2003-09-29 2005-04-07 Cj Corporation Sustained-release formulations
JP2005104914A (ja) * 2003-09-30 2005-04-21 Kyowa Yakuhin Kogyo Kk 塩基性薬剤含有製剤
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162737A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
AU2003286415A1 (en) * 2003-12-03 2005-06-24 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21702A (en) * 2004-01-29 2005-08-31 Lek Farmacevtska Druzba Dd Preparation of amorphous form of tamsulosin
JP4603803B2 (ja) * 2004-01-30 2010-12-22 大洋薬品工業株式会社 放出制御医薬組成物およびこれを用いる製剤
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
CN1895241B (zh) * 2005-07-12 2010-05-12 可隆制药株式会社 盐酸坦洛新的口服长效性小药丸组成物及其制造方法
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR20070044911A (ko) * 2005-10-26 2007-05-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
EP2026766A1 (en) * 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
EP2042169A1 (en) * 2007-09-26 2009-04-01 LEK Pharmaceuticals D.D. Controlled release tamsulosin hydrochloride tablets and a process of making them
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
TWI488659B (zh) * 2011-05-25 2015-06-21 Taiho Pharmaceutical Co Ltd Containing tegafur, gemcitabine, and otiracazide
CN102579392A (zh) * 2012-03-30 2012-07-18 重庆科瑞制药(集团)有限公司 一种含有盐酸坦索罗辛的缓释制剂及其制备方法
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3292864A1 (en) 2017-10-12 2018-03-14 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2019072404A1 (en) 2017-10-12 2019-04-18 Synthon B.V. MODIFIED RELEASE COMPRESSED COMPOSITION COMPRISING MIRABEGRON
PL3697392T3 (pl) 2017-10-17 2024-03-25 Synthon B.V. Tabletki zawierające tamsulosynę i solifenacynę

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088551A1 (en) * 1998-06-26 2001-04-04 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions for treating evacuatory insufficiency

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
WO1994009785A2 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
WO1995002419A1 (fr) * 1993-07-14 1995-01-26 Yamanouchi Pharmaceutical Co., Ltd. Remede agissant contre le dysfonctionnement urinaire associe a l'hypertrophie de la prostate
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
JPH09323926A (ja) * 1996-03-15 1997-12-16 Nikken Chem Co Ltd バルプロ酸ナトリウムの徐放性錠剤
AU7888298A (en) * 1997-01-03 1998-07-31 Elan Corporation, Plc Sustained release cisapride minitablet formulation
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
JP4221068B2 (ja) * 1997-12-17 2009-02-12 興和創薬株式会社 テオフィリン徐放性錠剤及びその製造方法
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
JP2000080032A (ja) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd 排出障害治療剤
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE313319T1 (de) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
WO2001010436A1 (fr) * 1999-08-09 2001-02-15 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees au traitement de l'uropathie inferieur
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
WO2003009831A1 (en) * 2001-07-27 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
NZ532589A (en) * 2001-11-07 2005-02-25 Synthon Bv Tamsulosin tablets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088551A1 (en) * 1998-06-26 2001-04-04 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions for treating evacuatory insufficiency

Also Published As

Publication number Publication date
SI1443917T1 (sl) 2006-06-30
ZA200403430B (en) 2006-02-22
DE60221691T3 (de) 2019-04-04
SI1441713T1 (sl) 2007-10-31
RU2004117080A (ru) 2005-04-10
JP2005512997A (ja) 2005-05-12
IL161491A0 (en) 2004-09-27
EP1441713B1 (en) 2007-08-08
ATE321544T1 (de) 2006-04-15
NL1021822C2 (nl) 2003-07-15
CN1589139A (zh) 2005-03-02
DK1441713T3 (da) 2007-12-17
EP1441713A1 (en) 2004-08-04
EP1443917A1 (en) 2004-08-11
NO20042375L (no) 2004-08-09
CZ16809U1 (cs) 2006-08-28
CZ16814U1 (cs) 2006-08-28
ZA200403281B (en) 2005-12-13
PT1443917E (pt) 2006-06-30
ATE369128T2 (de) 2007-08-15
CA2464689A1 (en) 2003-05-15
RU2335280C2 (ru) 2008-10-10
JP2005511591A (ja) 2005-04-28
IL161525A (en) 2012-12-31
HUP0402004A3 (en) 2008-08-28
DE60221691D1 (de) 2007-09-20
EP1441713B2 (en) 2018-11-14
DK1443917T3 (da) 2006-07-17
CA2464689C (en) 2011-02-01
NZ532589A (en) 2005-02-25
DK1441713T4 (en) 2019-02-18
RU2004117081A (ru) 2005-03-20
DE60210315T2 (de) 2006-11-02
NL1021857A1 (nl) 2003-05-08
HUP0402004A2 (hu) 2005-01-28
IL161491A (en) 2009-07-20
NL1021857C2 (nl) 2004-01-09
ES2287333T3 (es) 2007-12-16
ES2287333T5 (es) 2019-04-29
DE20220415U1 (de) 2003-10-09
JP2011051995A (ja) 2011-03-17
NO20042374L (no) 2004-08-09
HUP0401978A2 (hu) 2005-01-28
AT9978U1 (de) 2008-07-15
EP1595538A2 (en) 2005-11-16
DK200500297U3 (da) 2006-03-10
DE60221691T2 (de) 2008-04-30
CA2465110A1 (en) 2003-05-15
NO340960B1 (no) 2017-07-31
EP1443917B1 (en) 2006-03-29
PT1441713E (pt) 2007-08-28
CZ16813U1 (cs) 2006-08-28
SI1441713T2 (sl) 2019-03-29
DE20221486U1 (de) 2006-02-02
WO2003039531A1 (en) 2003-05-15
US20030147955A1 (en) 2003-08-07
WO2003039530A1 (en) 2003-05-15
CN1298317C (zh) 2007-02-07
EP1595538A3 (en) 2006-02-22
IL161525A0 (en) 2004-09-27
DE60210315D1 (de) 2006-05-18
HU230830B1 (hu) 2018-07-30
CN102327250A (zh) 2012-01-25
US20030147950A1 (en) 2003-08-07
NL1021822A1 (nl) 2003-05-08
HUP0401978A3 (en) 2008-07-28
CN1652760A (zh) 2005-08-10
RU2311903C2 (ru) 2007-12-10
ES2256544T3 (es) 2006-07-16
NZ532592A (en) 2005-02-25
JP5536610B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
AU2002301845B2 (en) Modified release tamsulosin tablets
JP2010090168A (ja) 医薬組成物
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
JP2009542647A (ja) メマンチン医薬組成物
US20080280981A1 (en) Tranexamic acid formulations
KR20010086062A (ko) 고가용성 약물용 서방성 메트리스 시스템
CA2182004C (en) Film coated tablet of paracetamol and domperidone
WO2004078111A2 (en) Extended release minocycline compositions and processes for their preparation
WO2009027786A2 (en) Matrix dosage forms of varenicline
US20050142193A1 (en) Galantamine formulations
CA2893480C (en) Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN115804774A (zh) 一种噁拉戈利的药物组合物，包含其的药物制剂，及其应用
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide
NZ541975A (en) Storage-stable and bio-stable formulations of ace inhibitors including enalapril maleate and quinapril hydrochloride, and methods for preparation thereof
AU2013202441A1 (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired